Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03714555 · ClinicalTrials.gov registry record · Phase 2
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
A Phase 2 study, sponsored by HonorHealth Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03714555: Clinical Trial Phase 2 study, sponsored by HonorHealth Research Institute.
NCT03714555 is a Phase 2 study that was terminated before completion, run by HonorHealth Research Institute. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03714555, a Phase 2 study, was terminated before completion, sponsored by HonorHealth Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label Phase 2 Pilot study to evaluate Disulfiram + Copper Gluconate in patients metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel (Abraxane) plus gemcitabine (Gemzar) or FOLFIRINOX or single-agent gemcitabine (Gemzar). Patient must have received a minimum of 8 weeks of treatment and have rising CA-19-9 levels in the absence of radiographic evidence of progression.
Primary Outcome
Change in plasma CA19-9 level (at least 30%) from baseline
Interventions
- DIAGNOSTIC_TEST Tumor Imaging
- OTHER Physical Exam
- DIAGNOSTIC_TEST Safety Laboratories
- OTHER AE Assessment
- OTHER Concomitant Medication Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2020-07-29 |
| Phase | Phase 2 |
Why NCT03714555 stopped before completion
NCT03714555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Tumor Imaging is the first listed.
NCT03714555 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03714555 about?
NCT03714555 is a clinical study titled "Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine". This is an open-label Phase 2 Pilot study to evaluate Disulfiram + Copper Gluconate in patients metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel (Abraxane) plus gemcitabine (Gemzar) or FOLFIRINOX or single-agent gemcitabine (Gemzar). Patient must have received a ...
What is the current status of trial NCT03714555?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-10-17. Estimated completion is 2020-07-29.
What interventions are being tested in trial NCT03714555?
The interventions under investigation include: Tumor Imaging (DIAGNOSTIC_TEST), Physical Exam (OTHER), Safety Laboratories (DIAGNOSTIC_TEST), AE Assessment (OTHER), Concomitant Medication Review (OTHER).
Who is sponsoring clinical trial NCT03714555?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03714555's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI